Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?

References

• Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–5.
   PubMed Web of Science ®Google Scholar
• Norum J, Nieder C. Treatments for metastatic prostate cancer (mPC): a review of costing evidence. Pharmacoeconomics. 2017;35:1223–1236.
   PubMed Web of Science ®Google Scholar
• Nieder C, Haukland E, Mannsåker B, et al. Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer. Oncol Lett. 2016;12:2930–2935.
   PubMed Web of Science ®Google Scholar
• Delanoy N, Hardy-Bessard AC, Efstathiou E, et al. Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database. Eur Urol Oncol. 2018;1:467–475.
   PubMed Web of Science ®Google Scholar
• Akaza H, Procopio G, Pripatnanont C, et al. Metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: treatment patterns from the PROXIMA prospective registry. J Glob Oncol. 2018;4:1–12.
   PubMed Web of Science ®Google Scholar
• Nieder C, Dalhaug A, Haukland E, et al. Contemporary radiooncological management of bone metastases from breast cancer: factors associated with prescription of different fractionation regimens (short or long course) in a rural part of North Norway with long travel distance. Int J Circumpolar Health. 2017;76:1270080.
   PubMed Web of Science ®Google Scholar
• Nieder C, Norum J, Spanne O, et al. Does distance to treatment centre influence the rate of palliative radiotherapy in adult cancer patients? Anticancer Res. 2009;29:2641–2644.
   PubMed Web of Science ®Google Scholar
• Arendt J. Biological rhythms during residence in polar regions. Chronobiol Int. 2012;29:379–394.
   PubMed Web of Science ®Google Scholar
• Juvani S, Isola A, Kyngäs H. The northern physical environment and the well-being of the elderly aged over 65 years. Int J Circumpolar Health. 2005;64:246–256.
   PubMedGoogle Scholar
• Luong K, Nguyen LT. The beneficial role of vitamin D and its analogs in cancer treatment and prevention. Crit Rev Oncol Hematol. 2010;73:192–201.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23:1803–1808.
   PubMed Web of Science ®Google Scholar
• Norum J, Nieder C. Socioeconomic characteristics and health outcomes in Sami speaking municipalities and a control group in northern Norway. Int J Circumpolar Health. 2012;71:19127.
   PubMed Web of Science ®Google Scholar
• Nieder C, Haukland E, Mannsåker B, et al. Initiation of systemic therapy during the last 30 days of life in patients with metastatic castration-resistant prostate cancer. Anticancer Res. 2019;39:335–340.
   PubMed Web of Science ®Google Scholar
• Voskarides K. The “cancer-cold” hypothesis and possible extensions for the Nordic populations. Scand J Public Health. 2019;47:477–481.
   Web of Science ®Google Scholar
• Lorente D, Fizazi K, Sweeney C, et al. Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus. 2016;2:488–498.
   PubMedGoogle Scholar
• Tampellini M, Polverari RS, Ottone A, et al. Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Chronobiol Int. 2015;32:1359–1366.
   PubMed Web of Science ®Google Scholar
• de la Haba-rodríguez J, Rodríguez-Lescure A, Ruiz A, et al. Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat. 2011;125:273–278.
   Web of Science ®Google Scholar
• Nieder C, Dalhaug A, Haukland E, et al. Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival? Int J Circumpolar Health. 2019;78:1620086.
   PubMed Web of Science ®Google Scholar
• Baade PD, Yu XQ, Smith DP, et al. Geographic disparities in prostate cancer outcomes–review of international patterns. Asian Pac J Cancer Prev. 2015;16:1259–1275.
   PubMedGoogle Scholar
• Charlton M, Schlichting J, Chioreso C, et al. Challenges of rural cancer care in the USA. Oncology (Williston Park). 2015;29:633–640.
   PubMed Web of Science ®Google Scholar
• Young TK, Kelly JJ, Friborg J, et al. Cancer among circumpolar populations: an emerging public health concern. Int J Circumpolar Health. 2016;75:29787.
   PubMed Web of Science ®Google Scholar